China startup Megvii secures $750m funding for AI-powered solutions
Category: #tech  By Mateen Dalal  Date: 2019-05-10
  • share
  • Twitter
  • Facebook
  • LinkedIn

China startup Megvii secures $750m funding for AI-powered solutions

The round brings Megvii’s valuation to more than $4 billion ahead of a planned initial public offering (IPO) in Hong Kong

Reports confirms that Megvii Technology, a Chinese artificial intelligence provider also known as Face++, has recently secured $750 million in a new round of funding.

Sources familiar with the matter suggested that the latest funding round brings Megvii’s valuation to more than $4 billion, ahead of a planned initial public offering (IPO) in Hong Kong later this year. Bank of China Group Investment, a private equity unit of the state bank has led the fundraising with $200 million investment.

Apparently, ICBC Asset Management Co, Macquarie Group, and a solely owned subsidiary of the Abu Dhabi Investment Authority, one of the largest sovereign wealth funds in the world, also joined the new round of funding. Along with this, the existing investor Alibaba Group had also participated in this round.

Sources further added that Megvii Technology is also supported by Foxconn Technology and has employed JPMorgan, Goldman Sachs, and Citigroup to work on its Hong Kong IPO. In December, it was informed that Megvii was aiming to secure $500 million in a new round of funding.

According to the sources, these proceeds will primarily be used to boost technology capabilities of Megvii in deep learning, to finance its global expansion and speed up the commercialization of its AI-enabled solutions, along with recruiting talent.

Seemingly, the fundraising comes at a time when Beijing plans to create a global closed-circuit television surveillance network (CCTV) and become a global leader in AI technology, a technology that is gradually becoming key to several sectors. Megvii provides facial recognition solution for the online payment unit of Alibaba, sources added.

A competitor of Megvii, SenseTime Group Ltd has secured over $600 million from SoftBank and its Vision Fund, raising its value to about $7.6 billion.

Reportedly in 2018, investments in the AI sector had increased to $2.1 billion through total 88 deals, which is more than four times the total value in the past two years.

Source Credit: https://www.reuters.com/article/us-megvii-fundraising/chinese-ai-start-up-megvii-raises-750-million-ahead-of-planned-hk-ipo-idUSKCN1SE138

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Ambrx partners with Bristol-Meyers to initiate Relaxin clinical trial
Ambrx partners with Bristol-Meyers to initiate Relaxin clinical trial
By Mateen Dalal

Ambrx will receive additional development payments with Bristol-Meyers’ initiation of the Phase 1 clinical trial for Relaxin Ambrx Inc., a biopharmaceutical company focused on developing protein therapeutics, has recently announced that Bristo...

LifeSpan Bio acquires Everest Biotech to expand reagent portfolio
LifeSpan Bio acquires Everest Biotech to expand reagent portfolio
By Mateen Dalal

The transaction will be LifeSpan BioSciences’ second investment this year following its Nordic-MUbio acquisition LifeSpan BioSciences (LSBio), a provider of life science research reagents and antibodies, has recently announced that it has acqu...

AbbVie buys Mavupharma to target STING pathway for cancer treatment
AbbVie buys Mavupharma to target STING pathway for cancer treatment
By Mateen Dalal

AbbVie Inc., a US-based pharmaceutical company recently announced acquisition of Mavupharma, a Seattle-based biopharmaceutical company, which is focused on innovative strategies to target the STimulator of INterferon Genes pathway for the treatment o...